BACKGROUND
New cancer medicines increasingly depend on molecular testing, from low-cost immunohistochemistry to expensive genomic diagnostics. The WHO Model List of Essential Medicines (EML) guides access to priority medicines. We aimed to analyse uptake trends for essential cancer medicines in 71 countries and two wor...
Kerstin N. Vokinger, S. Hediger, R. Casolino et al.· The Lancet Oncology· 0 citations
Cancer susceptibility testing is rapidly advancing beyond specialist genetics clinics into routine oncology and population-level genomics initiatives. This expansion positions germline pathogenic variants in cancer susceptibility genes and polygenic risk scores as crucial tools for precision prevention, surveillance, a...
Clare Turnbull, Sandra Perdomo, S. Domchek et al.· The Lancet Oncology· 1 citation
Without robust data stewardship, including effective data sharing and global integration, the potential of cancer genomics will remain fragmented across projects, platforms, and jurisdictions, and this disaggregation limits reproducibility, equity, patient benefit, and societal value.
D. Torrents, Oliver Hofmann, K. Cranston et al.· EBioMedicine· 1 citation
The Commission developed a value-based resource-stratified implementation framework, a system-readiness assessment tool, a precision oncology workforce competency-based framework, a precision oncology monitoring and evaluation framework, and principles for responsible data sharing and health-system learning.
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.